Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Diabetes Therapy
U.S. FDA approves Levemir
July 24th, 2005
Novo Nordisk, Inc., (NVO) announced that the U.S. Food and Drug Administration (FDA) has approved Levemir (insulin detemir [rDNA origin] injection) for the treatment of diabetes mellitus (type 1 and type 2). Levemir is a long-acting form of insulin that provides up to a 24-hour duration of action and has been shown to cause little weight change, according to the company. "Experts agree there is a significant need for consistent good control of patients' glucose levels, which is associated with a reduced risk of diabetes complications," said Peter Aurup, MD, vice president of the clinical development, medical, and regulatory affairs department. "The...
Source: Medical Letter on the CDC & FDA (2005-07-24)
|
